Pharmacy
Providers gain an estimated $4.5 billion in savings each year from the drug industry subsidy.
A six-month Kaiser Health News investigation found that the orphan drug program intended to help desperate patients is being manipulated by drugmakers.
Bill would require manufacturers to disclose to the insurance department the costs of production for drugs with average wholesale prices greater than $5,000 annually.
Experts say the device's price surge is way out of step with production costs, and a needless drain on healthcare resources.
PBM's facade as pro-consumer actors is cracked, will continue to erode as new scrutiny is leveled on them, says Rosenbloom.
Records reveal additional instances where Price set aside his priority of budget discipline in favor of special medical interests.
Generic drug manufacturers retained 23 percent that same year, totaling about $108 billion, and non-manufacturing drug entities retained 27 percent.
Settlement will require McKesson to hire an independent monitor to assess compliance, the first of its kind in a CSA civil penalty settlement, the DOJ said.
Many orphan medicines, originally developed to treat diseases affecting fewer than 200,000 people, come with astronomical price tags.
Mylan's brand-name EpiPen costs $649.99 for a two pack; its authorized generic costs roughly $340, CVS said.